Kraig Biocraft Laboratories Inc (KBLB)

[TRUISM]

Also, remember that BT's and Spiber have millions of dollars

Add AMSILK to the list:


––––––––––– PRESS RELEASE –––––––––––

AMSilk grows with additional capital – ramp-up of BIOSTEEL® production

Planegg, July 11, 2016 – AMSilk GmbH, the world’s first industrial supplier of synthetic silk molecules, has raised new capital through a further financing round. In total, a double-digit million EURO amount has been raised by the company so far. AMSilk can thus advance its further growth especially in the business divisions Medical Technology and Industrial Applications & Textiles. For subscription of the capital increase, AMSilk succeeded in winning AT Newtec and MIG, the existing institutional investors.

“We very much appreciate the trust and confidence which our longtime investors AT Newtec and MIG show us with their add-on investments. For us this is a wonderful confirmation that our products are valued by the market and that they have a promising future. After many years of development we are now in the phase of commercializing our products including AMSilk high- performance biopolymers for use in medical technology, cosmetic and personal care products as well as our BIOSTEEL® fibers in industrial applications & textiles”, states Jens Klein, CEO of AMSilk.

„AMSilk and its innovative product idea of using a biotechnological process to develop an organic high-performance material modelled on spider silk has convinced us from the beginning. The company has already introduced a number of products and applications into the market and is ready to launch further products. During the current round of financing we thus did not hesitate to continue investing in the company in order to be able to participate in the future success of AMSilk”, says Dr. Matthias Kromayer, Member of the Executive Board of MIG and Deputy Chairman of the Supervisory Board of AMSilk.

Capital to be used for funding further growth and product development

The capital raised will allow AMSilk to implement the next steps of their growth strategy. Plans include increasing production of the high-performance fiber BIOSTEEL®, financing the clinical studies of medical products and expanding the distribution activities of the cosmetic ingredients and personal care division.

Together with a leading European manufacturer of breast implants, AMSilk plans to conduct a clinical study on breast implants coated with AMSilk silk biopolymers. The market introduction of the silk-coated breast implants, whose tolerability is significantly higher compared to conventional breast implants, is expected to take place already in 2017.

In the field of fiber production, the focus initially is on co-operations with textile manufacturers. AMSilk BIOSTEEL® fibers are very robust, anti-bacterial, transport moisture and ensure a high wearing comfort.
Additionally, AMSilk plans further investments in the field of application technology to use the AMSilk high-performance biopolymers in cosmetic ingredients as well as to further enhance the patent position of the company, which currently includes more than 20 patent families.

About the investors

AT Newtec GmbH, one of the investment subsidiaries of Athos Service GmbH and Santo Holding, behind which stand the two brothers Dr. Andreas und Dr. Thomas Strüngmann, founders of the pharmaceutical company Hexal, is the lead investor of AMSilk GmbH since 2008. MIG Fonds (MIG Verwaltungs AG), are also invested in AMSilk for 8 years. AT Newtec and MIG invest in young promising non-listed companies.





Blessings to All

TRUTH